Haleon (LSE:HLN) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:HLN Haleon PLC LSE:HLN
73 GF Score
Price £3.43
GF Value £3.75
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Haleon Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

LSE:HLN
73GF Score
Haleon PLC LSE:HLN
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Haleon (LSE:HLN) Overvalued in 2026?

Based on GuruFocus' analysis, Haleon stock appears to be undervalued. The current stock price of £3.43 is trading 8.6% below its estimated GF Value™ of £3.75. GuruFocus considers Haleon to be Fairly Valued.

Key valuation signals for LSE:HLN:

  • Interest Expense (Positive):
  • GF Value™: £3.75 vs. price of £3.43 (8.6% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the LSE:HLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haleon Business Description

Address The Heights, Building 5, First Floor, Weybridge, Surrey, GBR, KT13 0NY
Haleon PLC is a consumer healthcare company formed from the combination of the consumer health businesses of GSK, Pfizer, and Novartis, and listed as a standalone company in July 2022. It develops, manufactures, and markets over-the-counter medicines, oral care products, vitamins and supplements, and digestive health remedies. Its portfolio includes global brands such as Sensodyne, Parodontax, Advil, Voltaren, Centrum, Caltrate, Tums, and Emergen-C, alongside regional brands tailored to local markets. Haleon sells primarily through pharmacies, grocery and mass retail chains, and online channels, serving consumers directly rather than through prescription-based reimbursement. Its revenue comes mainly from product sales across categories including oral health, pain relief, respiratory health, digestive health, and vitamins, minerals, and supplements. The company operates across North America, Europe, the Middle East and Africa, Latin America, and Asia-Pacific, with a significant share of sales generated outside its home market of the United Kingdom.
73GF Score

Get the complete analysis for LSE:HLN

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£3.43
Price
£3.75
GF Value